A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.

Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept® Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain. The transaction includes an upfront cash payment of $850 million and undisclosed additional contingent payments based on sales performance over the next three years.

As the only U.S. Food and Drug Administration-cleared system for vertebrogenic pain, the Intracept system is a minimally invasive, implant-free outpatient procedure. The therapy uses targeted radiofrequency energy to stop the basivertebral nerve from transmitting pain signals to the brain and is designed to improve function and provide long-term relief. In the U.S., there is an estimated population of approximately 5.3 million people living with vertebrogenic pain.1

″We anticipate this novel, clinically-backed technology can support our category leadership strategy while expanding access to care for individuals who need personalized treatment,″ said Jim Cassidy, president, Neuromodulation, Boston Scientific. ″Upon close, we look forward to working with the Relievant team to explore opportunities to bring this high-growth therapy to a wider population of people living with chronic low back pain.″

Boston Scientific expects to close the transaction in the first half of 2024, subject to satisfaction of customary closing conditions. Relievant is expected to generate sales in excess of $70 million in 2023 and to deliver year-over-year growth in excess of 50% in 2024. On an adjusted basis, the transaction is expected to be immaterial to adjusted earnings per share (EPS) in 2024, slightly accretive in 2025, and increasingly accretive thereafter. On a GAAP basis, the transaction is expected to be more dilutive due to amortization expense and acquisition-related charges.

“Today is an exciting step forward to shaping the future of chronic low back pain with Boston Scientific as a leader in the interventional chronic pain space,″ said Tyler Binney, president and CEO of Relievant. ″This is a testament to the exceptionally talented Relievant team and the innovative engine behind the Intracept system. Together with Boston Scientific, we can accelerate our journey to provide life-changing relief to patients by transforming the diagnosis and treatment of vertebrogenic pain.″

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The acquisition of Shockwave further extends Johnson & Johnson MedTech’s position in cardiovascular intervention and accelerates its shift into higher-growth markets.
“The acquisition of Empelvic reinforces our commitment to comprehensive health solutions for intimate conditions,” said Adam Mumford, Director of Medical Devices at Owen Mumford. “By combining Owen Mumford's global expertise with Empelvic's innovative product, we aim to provide enhanced support and choices for individuals seeking pelvic health solutions.”
"The acquisition of Beyond HME represents a pivotal moment for ACU-Serve as we continue to pursue strategic growth opportunities in the healthcare sector," said Jim Knight, President of ACU-Serve. "Beyond HME's reputation for excellence and its focus on re-supply services complement our existing offerings, positioning us for even greater success in meeting the evolving needs of our clients."
Avant Technologies CEO Timothy Lantz: “We are excited about this opportunity to accelerate Avant’s growth within the healthcare sector and create new value for our customers and shareholders. This acquisition will serve to further strengthen our financial position, unlock new growth opportunities in one of the top segments of AI adoption, and bolster our internal product development and client services capabilities.”
"Thanks to the nature of software, our platform can distribute new, advanced and validated digital diagnostics to the market globally with unprecedented speed," said Linus Health CEO and Co-Founder David Bates, PhD. "As with any chronic illness, earlier detection of brain-related disabilities allows for intervention that can delay, modify or even prevent progression of the disease. It's why we are engineering the most inclusive approach to assessing and monitoring brain function, one that includes speech and movement, in addition to memory and other neurological functions."

By using this website you agree to accept Medical Device News Magazine Privacy Policy